[{"id":"5ede9316-e2bc-4467-ba77-03f42735b0d4","acronym":"QUILT-3.061","url":"https://clinicaltrials.gov/study/NCT04052061","created_at":"2021-01-18T19:52:05.955Z","updated_at":"2025-02-25T13:39:55.192Z","phase":"Phase 1","brief_title":"QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT04052061 - QUILT-3.061","lead_sponsor":"ImmunityBio, Inc.","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19.t-haNK"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/16/2019","start_date":" 09/16/2019","primary_txt":" Primary completion: 09/18/2021","primary_completion_date":" 09/18/2021","study_txt":" Completion: 08/19/2022","study_completion_date":" 08/19/2022","last_update_posted":"2025-02-21"},{"id":"736082c4-cb8f-4038-ae24-2c9486718043","acronym":"BP41072","url":"https://clinicaltrials.gov/study/NCT04077723","created_at":"2021-01-18T19:58:08.759Z","updated_at":"2025-02-25T13:39:56.985Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT04077723 - BP41072","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20 • CD19","pipe":" | ","alterations":" CD20 expression • CD19 expression","tags":["CD20 • CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm) • englumafusp alfa (RG6076)"],"overall_status":"Recruiting","enrollment":" Enrollment 498","initiation":"Initiation: 08/13/2019","start_date":" 08/13/2019","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-21"},{"id":"65a39e57-0fe4-43a3-8e14-9aae8f76d3a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06124157","created_at":"2023-11-09T16:12:44.229Z","updated_at":"2025-02-25T14:42:30.057Z","phase":"Phase 3","brief_title":"A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)","source_id_and_acronym":"NCT06124157","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • KIT • PDGFRA • CD19 • PDGFRB • CSF1R","pipe":" | ","alterations":" CD19 expression","tags":["ABL1 • KIT • PDGFRA • CD19 • PDGFRB • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Starasid (cytarabine ocfosfate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 680","initiation":"Initiation: 05/29/2025","start_date":" 05/29/2025","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2025-02-14"},{"id":"c0f4d14f-2257-447f-847c-ebe3a10d55e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01087294","created_at":"2023-05-20T02:04:59.343Z","updated_at":"2025-02-25T15:32:08.685Z","phase":"Phase 1","brief_title":"Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation","source_id_and_acronym":"NCT01087294","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"],"overall_status":"Completed","enrollment":" Enrollment 85","initiation":"Initiation: 08/04/2010","start_date":" 08/04/2010","primary_txt":" Primary completion: 03/08/2024","primary_completion_date":" 03/08/2024","study_txt":" Completion: 04/02/2024","study_completion_date":" 04/02/2024","last_update_posted":"2025-02-11"},{"id":"818c72a5-92a4-43b8-8e83-ad27609f899b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05667506","created_at":"2022-12-28T16:01:43.670Z","updated_at":"2025-02-25T15:27:48.147Z","phase":"Phase 1/2","brief_title":"A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)","source_id_and_acronym":"NCT05667506","lead_sponsor":"Juventas Cell Therapy Ltd.","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Yorwida (inaticabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 02/07/2023","start_date":" 02/07/2023","primary_txt":" Primary completion: 07/30/2025","primary_completion_date":" 07/30/2025","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-02-10"},{"id":"d7d0a6de-b0e3-4648-b4e9-ec298fd54104","acronym":"B-ALL","url":"https://clinicaltrials.gov/study/NCT06009107","created_at":"2024-03-13T08:35:11.520Z","updated_at":"2025-02-25T16:33:38.314Z","phase":"Phase 1/2","brief_title":"A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)","source_id_and_acronym":"NCT06009107 - B-ALL","lead_sponsor":"Juventas Cell Therapy Ltd.","biomarkers":" IL6","pipe":" | ","alterations":" CD19 expression","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • HY004"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/30/2027","study_completion_date":" 12/30/2027","last_update_posted":"2025-02-07"},{"id":"5ed07491-b740-48b9-9e27-6d61db55c929","acronym":"","url":"https://clinicaltrials.gov/study/NCT03373071","created_at":"2021-01-18T16:38:50.176Z","updated_at":"2025-02-25T16:44:17.022Z","phase":"Phase 1/2","brief_title":"Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/refractory CD19+ ALL and NHL","source_id_and_acronym":"NCT03373071","lead_sponsor":"Bambino Gesù Hospital and Research Institute","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 12/23/2017","start_date":" 12/23/2017","primary_txt":" Primary completion: 05/11/2021","primary_completion_date":" 05/11/2021","study_txt":" Completion: 01/24/2025","study_completion_date":" 01/24/2025","last_update_posted":"2025-02-05"},{"id":"d6ba98f0-0642-4147-9072-780ec6d83e99","acronym":"","url":"https://clinicaltrials.gov/study/NCT03751709","created_at":"2021-01-18T18:23:36.975Z","updated_at":"2025-02-25T16:44:29.699Z","phase":"Phase 1","brief_title":"Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL","source_id_and_acronym":"NCT03751709","lead_sponsor":"Cedars-Sinai Medical Center","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 02/14/2020","start_date":" 02/14/2020","primary_txt":" Primary completion: 03/27/2023","primary_completion_date":" 03/27/2023","study_txt":" Completion: 11/12/2024","study_completion_date":" 11/12/2024","last_update_posted":"2025-02-05"},{"id":"b1018fa9-fe4d-453b-84e2-5cea26a0b9e5","acronym":"NCI-2016-01300","url":"https://clinicaltrials.gov/study/NCT02879695","created_at":"2021-01-18T14:08:12.480Z","updated_at":"2025-02-25T16:51:44.591Z","phase":"Phase 1","brief_title":"Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia","source_id_and_acronym":"NCT02879695 - NCI-2016-01300","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD19 • CD34 • MME","pipe":" | ","alterations":" CD19 expression","tags":["CD19 • CD34 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Blincyto (blinatumomab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 10/25/2017","start_date":" 10/25/2017","primary_txt":" Primary completion: 05/22/2023","primary_completion_date":" 05/22/2023","study_txt":" Completion: 07/18/2025","study_completion_date":" 07/18/2025","last_update_posted":"2025-02-04"},{"id":"3620a279-00d9-40e2-8835-c205c51f9360","acronym":"","url":"https://clinicaltrials.gov/study/NCT03792633","created_at":"2021-01-18T18:45:04.269Z","updated_at":"2025-02-25T16:59:53.561Z","phase":"Phase 2","brief_title":"Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL","source_id_and_acronym":"NCT03792633","lead_sponsor":"University of Pennsylvania","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e huCART19"],"overall_status":"Completed","enrollment":" Enrollment 106","initiation":"Initiation: 01/18/2019","start_date":" 01/18/2019","primary_txt":" Primary completion: 04/04/2024","primary_completion_date":" 04/04/2024","study_txt":" Completion: 04/04/2024","study_completion_date":" 04/04/2024","last_update_posted":"2025-02-03"},{"id":"71fc84c6-241a-4534-8cc7-be17409b90e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04276870","created_at":"2021-01-18T20:46:13.854Z","updated_at":"2025-02-25T17:30:11.424Z","phase":"Phase 2","brief_title":"Orphan Indications for CD19 Redirected Autologous T Cells","source_id_and_acronym":"NCT04276870","lead_sponsor":"Stephan Grupp MD PhD","biomarkers":" CD19 • KMT2A","pipe":" | ","alterations":" MLL rearrangement • CD19 expression","tags":["CD19 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kymriah (tisagenlecleucel-T)"],"overall_status":"Recruiting","enrollment":" Enrollment 133","initiation":"Initiation: 03/12/2020","start_date":" 03/12/2020","primary_txt":" Primary completion: 03/10/2028","primary_completion_date":" 03/10/2028","study_txt":" Completion: 03/10/2037","study_completion_date":" 03/10/2037","last_update_posted":"2025-01-30"},{"id":"f5de46f2-d18a-4c9b-9824-b8d60d25c24c","acronym":"RG1006269","url":"https://clinicaltrials.gov/study/NCT04257578","created_at":"2021-01-18T20:41:36.655Z","updated_at":"2025-02-25T14:58:51.439Z","phase":"Phase 1/2","brief_title":"Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma","source_id_and_acronym":"NCT04257578 - RG1006269","lead_sponsor":"University of Washington","biomarkers":" CD4","pipe":" | ","alterations":" CD19 expression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib) • Yescarta (axicabtagene ciloleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 12/02/2020","start_date":" 12/02/2020","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2031","study_completion_date":" 03/01/2031","last_update_posted":"2024-10-29"},{"id":"f0a201da-f378-4921-aead-597de9839f37","acronym":"REFUEL","url":"https://clinicaltrials.gov/study/NCT05460533","created_at":"2022-07-15T16:05:35.713Z","updated_at":"2025-02-25T15:54:32.296Z","phase":"Phase 2","brief_title":"A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)","source_id_and_acronym":"NCT05460533 - REFUEL","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD19 • IFNG","pipe":" | ","alterations":" CD19 expression","tags":["CD19 • IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kymriah (tisagenlecleucel-T)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 07/12/2022","start_date":" 07/12/2022","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-10-24"},{"id":"62765188-4060-4462-ba62-f845b4a31a33","acronym":"","url":"https://clinicaltrials.gov/study/NCT05442515","created_at":"2022-07-05T14:54:21.934Z","updated_at":"2024-07-02T16:34:25.864Z","phase":"Phase 1/2","brief_title":"CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies","source_id_and_acronym":"NCT05442515","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD19 • CD22","pipe":" | ","alterations":" CD19 expression • CD22 expression","tags":["CD19 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 12/28/2022","start_date":" 12/28/2022","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2029","study_completion_date":" 07/01/2029","last_update_posted":"2024-06-14"},{"id":"59201174-86d0-4c21-b519-220173f5e9be","acronym":"ENABLE","url":"https://clinicaltrials.gov/study/NCT04049513","created_at":"2021-01-18T19:51:32.910Z","updated_at":"2024-07-02T16:34:26.420Z","phase":"Phase 1","brief_title":"ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)","source_id_and_acronym":"NCT04049513 - ENABLE","lead_sponsor":"Malaghan Institute of Medical Research","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • WZTL-002 • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/11/2019","start_date":" 10/11/2019","primary_txt":" Primary completion: 06/12/2024","primary_completion_date":" 06/12/2024","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2024-06-13"},{"id":"d7a99f87-af15-49c9-a79c-a263479ceeab","acronym":"","url":"https://clinicaltrials.gov/study/NCT05219513","created_at":"2022-02-05T18:28:39.448Z","updated_at":"2024-07-02T16:34:26.627Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT05219513","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20 • CD19","pipe":" | ","alterations":" CD20 expression • CD19 expression","tags":["CD20 • CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm) • RG6333"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 02/18/2022","start_date":" 02/18/2022","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-06-13"},{"id":"438a6c38-27c0-498a-a4bb-5280c1fbcdf4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05114837","created_at":"2021-11-10T14:12:52.801Z","updated_at":"2024-07-02T16:34:26.797Z","phase":"Phase 1/2","brief_title":"Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL","source_id_and_acronym":"NCT05114837","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 09/01/2024","start_date":" 09/01/2024","primary_txt":" Primary completion: 08/01/2028","primary_completion_date":" 08/01/2028","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2024-06-12"},{"id":"dc060c11-ef1a-4e41-b660-edc9c517c35e","acronym":"CASSIOPEIA","url":"https://clinicaltrials.gov/study/NCT03876769","created_at":"2021-01-18T19:06:40.258Z","updated_at":"2024-07-02T16:34:27.333Z","phase":"Phase 2","brief_title":"Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients","source_id_and_acronym":"NCT03876769 - CASSIOPEIA","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kymriah (tisagenlecleucel-T)"],"overall_status":"Recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 06/24/2019","start_date":" 06/24/2019","primary_txt":" Primary completion: 10/19/2027","primary_completion_date":" 10/19/2027","study_txt":" Completion: 10/19/2027","study_completion_date":" 10/19/2027","last_update_posted":"2024-06-11"},{"id":"94c71a13-e74f-49dc-a1f8-7d536a6dd6ae","acronym":"","url":"https://clinicaltrials.gov/study/NCT04684147","created_at":"2021-01-19T20:47:16.231Z","updated_at":"2024-07-02T16:34:27.675Z","phase":"Phase 2","brief_title":"Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT04684147","lead_sponsor":"Juventas Cell Therapy Ltd.","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Yorwida (inaticabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/24/2020","start_date":" 12/24/2020","primary_txt":" Primary completion: 09/22/2022","primary_completion_date":" 09/22/2022","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-10"},{"id":"4b1e2885-ae3f-433a-8a0a-828ebea2022b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03448393","created_at":"2021-01-18T17:00:10.946Z","updated_at":"2024-07-02T16:34:37.765Z","phase":"Phase 1","brief_title":"CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies","source_id_and_acronym":"NCT03448393","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD19 • CD22","pipe":" | ","alterations":" CD19 expression • CD22 expression","tags":["CD19 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CD19/CD22 CAR T-cells • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 03/26/2018","start_date":" 03/26/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/31/2040","study_completion_date":" 12/31/2040","last_update_posted":"2024-06-06"},{"id":"f05359a0-1077-478c-8919-884404c2b3f4","acronym":"CARTROG","url":"https://clinicaltrials.gov/study/NCT06352242","created_at":"2024-04-08T18:25:11.662Z","updated_at":"2024-07-02T16:34:38.216Z","phase":"","brief_title":"Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma?","source_id_and_acronym":"NCT06352242 - CARTROG","lead_sponsor":"University Hospital, Montpellier","biomarkers":" CD20","pipe":" | ","alterations":" CD19 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 05/22/2024","start_date":" 05/22/2024","primary_txt":" Primary completion: 05/22/2026","primary_completion_date":" 05/22/2026","study_txt":" Completion: 05/22/2026","study_completion_date":" 05/22/2026","last_update_posted":"2024-06-05"},{"id":"f1bf4b85-b271-4210-9a40-9946f6a72d43","acronym":"","url":"https://clinicaltrials.gov/study/NCT06080191","created_at":"2023-10-12T21:13:56.143Z","updated_at":"2024-07-02T16:35:00.508Z","phase":"Phase 1","brief_title":"Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL","source_id_and_acronym":"NCT06080191","lead_sponsor":"Bambino Gesù Hospital and Research Institute","biomarkers":" CD19 • CD22","pipe":" | ","alterations":" CD19 expression","tags":["CD19 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 04/28/2024","start_date":" 04/28/2024","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/01/2041","study_completion_date":" 06/01/2041","last_update_posted":"2024-05-29"},{"id":"41b868a7-e7be-446b-8235-fde40165cb18","acronym":"","url":"https://clinicaltrials.gov/study/NCT05292898","created_at":"2022-03-23T13:53:39.110Z","updated_at":"2024-07-02T16:35:03.931Z","phase":"Phase 1","brief_title":"A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia","source_id_and_acronym":"NCT05292898","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" CD20 • CD22","pipe":" | ","alterations":" CD19 expression","tags":["CD20 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • LCAR-AIO"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/14/2022","start_date":" 03/14/2022","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-05-14"},{"id":"363e96eb-5e3f-442c-b58a-38eaeb74e6d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04684563","created_at":"2021-03-16T19:53:11.570Z","updated_at":"2024-07-02T16:35:04.117Z","phase":"Phase 1","brief_title":"huCART19-IL18 in NHL/CLL Patients","source_id_and_acronym":"NCT04684563","lead_sponsor":"University of Pennsylvania","biomarkers":" ALK • BCL2 • CD19 • BCL6","pipe":" | ","alterations":" CD19 expression • BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • BCL2 • CD19 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e huCART19 • huCART19-IL18"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 05/06/2021","start_date":" 05/06/2021","primary_txt":" Primary completion: 05/01/2036","primary_completion_date":" 05/01/2036","study_txt":" Completion: 05/01/2036","study_completion_date":" 05/01/2036","last_update_posted":"2024-05-13"}]